Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650
Completed · Phase 1
Conditions studied: Healthy Subjects
In brief
The purpose of this study is to determine the safety and tolerability of AV650 in healthy subjects given single and multi-doses under fasted and fed conditions.
Key facts
- Study ID
- NCT00364039
- Run by
- Avigen
- People needed
- 30
- Starts
- 2006-08-01
- Last updated by the study team
- 2007-02-28
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Non-smoking
- Body mass index between 18.5 and 29.9 kg/m2 or body mass index greater than 29.9 kg/m2 with good to excellent body fat percentage
You may not qualify if…
- Known hypersensitivity to lidocaine or non-steroidal anti-inflammatory agents (NSAIDS)
- History of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic, or psychiatric disease
- History of HIV or Hepatitis B
- History of symptomatic hypotension
- History of mental illness, drug addiction, drug abuse or alcoholism
- History of cancer
- History of inflammatory arthritis (rheumatoid, lupus, psoriatic arthritis)
- Current use of immunosuppressive therapy (systemic steroids, cyclosporine) or use of nasal or topical steroids
- History of gastric or duodenal ulcer disease
- History of severe physical injury, direct impact trauma or neurological trauma within 6 months of Study Day 1
- Female subjects who are pregnant or nursing
- Have donated blood within 90 days of Study Day -1
- Have received an investigational drug within 90 days of Screening
- Require regular use of antihistamines, H2 blockers (such as cimetidine, ranitidine), TCAs or SSRIs or who have taken these medications witin 14 days of Study Day 1
Where it is running
- SNBL Clinical Pharmacology Center — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.